Potentially Curable Cancers of the Esophagus and Stomach

Abstract

Gastric and gastroesophageal adenocarcinomas continue to be a significant health burden globally and collectively represent the third leading cause of cancer death. When metastatic, most patients succumb to their cancer because of a limited number of modestly effective regimens available today. The progress against these cancers has been slow compared to many other solid tumors despite many attempts. In depth molecular profiling is also not completed. Even when these cancers are localized, they impose significant challenges for the patient, relatives, and treating team alike. Localized gastric or gastroesophageal cancer is best managed by a multidisciplinary approach. This review will focus on the management of localized cancers by reviewing the current literature and explaining certain principles that help guide therapy of these patients. The future, however, will afford a number of opportunities including exploitation of the Cancer Genome Atlas (TCGA) generated initial data to identify novel targets and drugs, harnessing the prowess of the immune system, and finally, customizing therapy for each patient. Localized gastric or gastroesophageal cancer is best managed by a multidisciplinary approach and involves multimodality therapy of locally advanced disease and team work. The exploitation of the Cancer Genome Atlas (TCGA) generated initial data to identify novel targets and drugs, harnessing the prowess of the immune system, and finally, customizing therapy for each patient.

ncRNAs-mediated high expression of ITGB1 correlates with poor prognosis and tumor immune infiltration in gastric cancer

“…The poor prognosis and high aggressiveness of GC make it the third leading cause of cancer worldwide. Despite the adoption of various therapeutic strategies for GC patients, the overall prognosis remains unfavorable [24,25]. Clarifying the molecular mechanism underlying GC carcinogenesis is crucial for the development of novel therapeutic targets and identi cation of promising prognostic biomarkers to enhance patients' outcomes in managing this disease.…”